Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ACST plans to submit their NDA in mid 2020. This and a ton of other info can be found in their most recent presentation -
https://d1io3yog0oux5.cloudfront.net/_92d3db12f3d15e8a15e2ddd9c9dc1cc2/acastipharma/db/641/5797/pdf/Acasti+October+PPT+Print+1+per+page.pdfAcasti+October+PPT+Print+1+per+page_16045094929.pdf
The following was sent out to subscribers at 9:36 ET. This may murky the waters a little more for some. However, it will all come down to the clinical data.
What is Chen Buying? What is Chen Selling?
Letter 2256
December 23, 2019
Update:
Acasti Pharma Inc. (ACST) is going wild head of the important phase 3 top line data. I had discussion with management not long ago and I was promised the data would come out “before Christmas”. I thought we would have the data by now but it didn't happen so far. What happened what one week ago my friend George Haywood wrote a letter to his friends, including me, after AMRN got the approval, with his permission, I am posting it here.
“
…............
The issue before the Harris/Haywood jury is simple: will Acasti's drug CaPre (CP) perform better on the metrics in its Trilogy trial than Vascepa (VC) did in its Marine trial on a similar population, TGs between 500 and 1500 or 2000. They are measuring many things, the most important of which are TG, HDL, LDL, and HbA1c. I believe that if CP beats VC on all or even most of these, Acasti stock will soar. For some context, ACST is at a market cap of 200 million now, AMRN will be at roughly 11 billion when the stock starts trading today.
These two companies(AMRN and ACST) each have only one product, an N-3-containing drug derived from marine sources whose primary mechanism of action is thought to be TG lowering (but you and I both know the effects are pleiotropic). This 55-to-1 disparity between mkt caps should narrow dramatically if CP looks to be better than VC. Of course a disparity is justified because VC is approved for sale and CP has a long way to go on that front. Also, VC has done an outcome trial and CP has not. But the thinking is that FDA may start to look at N-3 drugs as a class, especially if the upcoming STRENGTH trial data from AstraZeneca is good, as I believe it will be. So maybe FDA would give a broad label to CP without an outcome trial, in which case it could be a blockbuster drug--with the expected effect on the company stock price.
So that is why we need to try to figure out what effect to expect on lipid profile when you give a daily dose of around 750 mg EPA+ 500 mg DHA + 2500 mg phospholipids for 12 weeks to a bunch of folks whose TG level is around 680. Acasti has said it plans to release data only on TG at first, and maybe a month later on HDL and LDL and HbA1c, but they might change their mind and try to release more than just TG results at first. If CP beats VC on TG-lowering, investors will assume (probably correctly) that it will have superior results on LDL and HDL also, and we are off to the races.
…...................”
In his email, Haywood was also critical about the trial and the results to be published that didn't emphasis the trilogy enough. As we know, Haywood is the largest shareholder of ACST and he voice carries a lot of weight. After reading the email, ACST management decided to wait till the secondary end points, which they were planning to release around the end of the year, to release them at once. So the new release date is likely in a week or two. In the mean time we had huge run of ACST stock. I suspect the first data, triglyceride lowering, is likely positive as it should be in the hands of a few people in the past week. From the chart, ACST broke out last week and pointing to 4-5 dollar range. It it runs to 4 before the data, I may take some profits
What is Chen Buying? What is Chen Selling?
Letter 2195
July 22, 2019
Update:
Last week was a big week for me, not only silver did great, my Neptune Wellness Solutions Inc. (NEPT) and Acasti Pharma Inc. (ACST) both exploded. NEPT did a financing with mostly large shareholders and insiders. Remember shorts were all over NEPT as they smell blood of a raise. Before I left for vacation, I asked large shareholders of NEPT to consider doing a financing at a small premium to send the shorts a strong message. I am very pleased to see this 4.4 financing mostly by large shareholders and insiders. My friend George Haywood called it “the most impressive insider buying I have ever seen!“ You can see from the filing, Perceptive increased its stake to 15%, CEO and Chairman put in 5 million despite they already owned millions of shares. Every large shareholders participated including my friend Haywood et al. Plus this financing comes with conditions that the buyers can't sell any shares, exisitng or new for months to come. Basically the shorts are in a box and getting ready to be squeezed hard. We should have very exciting news coming starting with closing the US plant this month.
ACST is doing great thanks to a new research report Oppenheimer came out. It gave 7 dollar target assuming 30% chance of success. Personally I believe the chance of success is more close to 90%. As I discussed, tens millions of shares will likely be purchased before the data readout in December. I am holding my shares here. If you don't wish to take any risks, you can sell some before the data and make it zero cost into the data, which is likely coming out in December.
Regards,
Chen
RE:RE:What is Chen Buying? What is Chen Selling?
More from Chen -
11/16/18 -
Biotechs are in deep corrections. My sense is that this is a good time to buy quality stocks at deep discount. I recently asked a good friend of mine who is a very experienced biotech guy. If I put a gun to your head, which of the biotechs you would buy now? He told me it would be Acasti Pharma Inc. (ACST) and Viking Therapeutics, Inc. (VKTX). ACST is truly beyond reasoning here, he said. They are full funded to phase 3 results and raised at one dollar without warrants. Trial results will start to come out in Q3 of 2019. AMRN already recovered, they will likely get the FDA approval for expansion of label in 2019. Next time this year, with positive results that we are expecting, he strongly believes ACST will be the best in class and should be trading at least 5+.
11/28/18 -
I had a good meeting with Acasti Pharma Inc. (ACST) management yesterday. They came to New York to marketing their company finally. They are fully funded for the two phase 3 next year. The first phase 3 will finish enrollment in December and trial readout can come out as early as Q3 of 2019. The second trial is about 3 month behind and will be finished by the end of 2019. They are working on partnerships around the world and could bring extra money and collaborations. They are also working on other indications. They want to complete pre-clinical trials to support Capre lower the blood sugar. Lower A1C was one of the secondary end points of the current two phase 3 trials. They want to be able to include it in the label if the trial goes as they hoped. Oppenheimer plans to launch research coverage in January. I think once the tax loss selling is finished, excitement could build ahead of next year's data. On valuation, ACST is very very cheap. Even based on AMRN pre-REDUCE-IT half a billion market cap. It should worth that much, or $5/share. If the data is spectacular as we hoped, Capre can be the next Lipitor that took the majority of the market share WITHOUT an outcome study like REDUCE-IT. In that case, ACST can worth $20-50/share or more. After all, the patients want and deserve only the best.
Read more at http://www.stockhouse.com/companies/bullboard?symbol=v.acst&postid=29176815#tv7UIMGaYpBpGMr0.99
9/24/18- 1000% upside according to Mackie Research -
https://www.cantechletter.com/2018/09/acasti-pharma-stock-has-1000-upside-mackie-research-says/
Very good info on ACST -
12/19/17 - http://www.alignresearch.co.uk/acasti-pharma/acasti-pharma-view-krill/
10/1/18 - http://www.alignresearch.co.uk/acasti-pharma/acasti-pharmaceuticals-market-begins-wake-upside-offer-capre-trials-prove-successful/
10/4/18 - http://www.alignresearch.co.uk/acasti-pharma/acasti-pharma-peer-success-shows-investors-could-make-a-krilling/
I'm here and enjoying this run!
Another forum -
https://finance.yahoo.com/quote/ACRX/community?p=ACRX
VLE.TO/PNWRF - From Malcolm Shaw last week -
http://hydracapital.ca/hydra-blog/time-to-talk-turkey-as-valeura-operations-restart-approaches
http://hydracapital.ca/hydra-blog/valeura-short-position-update
How do you think the nFusz employees felt when Rory was hyping the 20,000 subscription number during the 1st quarter while knowing that nobody was signing up?
Maybe they will bag 10,000 subscribers by the end of the year, maybe!!!
It's more likely that the share price will be sub penny. CEOs don't lie if their product has potential!!!
Hello!!!
Looking good here!!!
Maybe an analyst put out a good report this morning?
Exactly,
So, we've heard from 2 or 3 or maybe 5 of the hundreds and hundreds of followers here that have actually signed up for notifyCRM. Is it a red flag that share holders don't embrace the technology? I don't know.
What I do know is that Rory promised a Hawaii trip for his employees if nFusz signed up 20,000 users by the end of March.
He also said that we may blow past that number and stated that employees are dieting in anticipation of the trip. At that point the 20,000 number was in the bag, right?
Then the quarter ended with no mention of Hawaii and we were treated to the infamous -
We aren't going to reveal the numbers. Rory went on to say that revealing the numbers might hurt the Company if a large company was interested in signing up 2,000,000 employees (LOL). My translation of Rory's excuse for dumping the Hawii hype is that the adoption numbers for the first quarter are embarrassingly low.
IMO. If the revenue for the first quarter is embarrassingly low, after all of Rory's hyping, then the law firms will be circling.
I don't care about how many integrations nFusz has. That's meaningless. Paying customers determine the future of this Company and it's likely that there won't be that many until the end of quarter 3, if ever.
Having said this, I bought Friday at $1.22 and am hoping for a bounce.
The Statement of Ownership (sc -13g) must be filed if someone beneficially owns more than 5% of a security. It doesn't mean that the filer will be exercising or selling shares.
Thank You.
Don't be the last out the door.
Stating facts with links!
You're right. It's light years ahead.
"Add interactive elements to your videos to create a 2-way conversation with your viewers."
"Add interactive elements to your videos to create a 2-way conversation with your viewers."
Smart Integrations -
Oracle - Marketo - Salesforce - Microsoft - Google - SnapApp
https://www.vidyard.com/integrations/
"Add interactive elements to your videos to create a 2-way conversation with your viewers."
Smart Integrations -
Oracle - Marketo - Salesforce - Microsoft - Google - SnapApp
https://www.vidyard.com/integrations/
This is a great post!!!
Now that is funny.
I say kudos to people for not taking a profit. That is the reason people are up 1300%.
Thanks for the reply!
It's good to have a person here that has digital marketing experience!
From today's PR (underline by me) -
I emailed a question asking which quarter Rory was referring to when he said; I won't make you wait that long.
This is how I interpreted what Rory said, in written form (from memory) -
The year end financials are due by the end of March, the 1st qtr financials are due in May, (the second qtr is when sales will really kick in) but, I'm not going to make you wait that long.
IMO, it would be odd if Rory was already telling us that he planned to give us 2nd qtr numbers early while we are still in the 1st qtr.
Hopefully, Rory will address my question during todays radio show.
When I owned CTIX (now IPIX) and XXII, and wasn't signed up for the lending program, Fidelity called and asked if I was interested in loaning my shares. They are both OTC stocks. These calls didn't come until the share price was $3 or $4.
Do you know if Schwab lends shares from their mutual funds to the shorts. I asked and found out that Fidelity does. This is where most of the availability of shares to short comes from at Fidelity.
Then Schwab is different than Fidelity in that I have to call Fidelity and tell them which stock or stocks that I am unwilling to have them borrow.
I have participated in the Fully Paid Lending Program at Fidelity. I assume that all brokers handle their borrowing of shares the same way. However, it would make sense to call your broker and get their details.
There are 2 ways for a broker to borrow your shares -
1) You have a margin account and have a margin debit in that account. The margin debit means that you do not fully own the shares held in the account. This entitles the broker to borrow any or all shares of all securities held in the account without notifying you. You will not receive any interest on the shares borrowed from you.
2) Your broker calls you or you call your broker and a Fully Paid Lending Program agreement is completed by you and sent to your broker. This agreement entitles your broker to borrow any or all of the shares in your account (unless you specify shares that you don't want to loan) and you will be paid interest on the shares that are borrowed.
Your shares in your cash account should be safe from broker borrowing as should shares in a margin account that has no margin debit. However, call your broker to verify.
A sell order on a security does not protect it from borrowing. Having a cash account or a margin account with no margin debit does protect your shares from unwanted borrowing
As I stated, it came on after the tournament game.
Now I'm getting attacked for sharing my thoughts.
Have a good night.
I would say that males involved in porn are sluts as well
If a homophobe is someone who is not a homo, then, yes, I am one of them.
A women participating in porn is not a slut? She is now considered a business women?
60 minutes used to be above the National Enquirer.
Things have changed!
So, I watched the end of the basketball game and then 60 Minutes came on. I thought fine, I haven't seen 60 Minutes for years and was interested to see what they were doing these days and who they had for anchors. I used to like the Andy Rooney segments.
I almost puked when I saw what was happening in the lead segment. Anderson, take it in the pooper, Cooper was interviewing a slut and they were talking about a 2006 one night stand between the slut and our President. WTF!!!
I really like that Rory told us (last video) that we wouldn't have to wait until May for some first qtr numbers. Sounds to me like he is anxious to release them, so, they should be good. We may hear about first qtr revenue and subscriptions as early as the first week in April.
My gut tells me that this will be treated as huge news!!!
I did, 11 cents.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138675403
How about you?